Immunohistochemical study of BCL-2, PCNA and VIMENTIN markers in oral and laryngeal squamous cell carcinoma
(Comparative study)
Shaimaa F. muhsin M.SC. (1)
Assis.Prof. Kadhim A. Alsodani B.D.S., M.Sc(oral Path.)(2)
ABSTRACT
Background squamous cell carcinoma (SCC) may arise in any stratified squamous epithelium or muosa that has undergone squamous metaplasia.
Aims of the study: Immunohistochemical evaluation and comparison of PCNA, BCL-2 and VIMENTIN expressions in oral and laryngeal squamous cell carcinoma and correlating such expressions with the clinicopathological behavior in both sites.
Materials and Methods: This study was performed on thirty formalin-fixed, paraffin-embedded pathologically diagnosed oral and laryngeal SCC blocks for the period of June 2006 till July 2010.Age, sex, site and histologic grades were recognized. The samples were immunohistochemically stained with monoclonal antibodies toBCL-2, PCNA and VIMENTIN.
Results: The age of the patients with squamous cell carcinoma of the oral cavity was between 40 and 86 and between 32 and 66 years in larynx. The male/female ratio was 10/5 and 8/7 for oral and Larynx respectively. The majority of the cases of Oral squamous cell carcinoma were located on the buccal mucosa, Whereas Laryngeal squamous cell carcinoma cases were distributed on glottic mainly..No significant statistical difference in the age and gender between the two groups .Histological grading was recognized for each case of oral and laryngeal squamous cell carcinoma . Two thirds of the oral cases were well differentiated. While 8 of the fifteen cases were moderately differentiated SCC. Regarding histological grading there was no statistically significant difference between the two groups .PCNA expressed in 14 of the fifteen oral cases whereas in laryngeal, 12 cases were positive.Collectively, 9 of the 30 cases were positive for vimentin antibody with different score values,.Bcl-2 was expressed in one case only from fifteen immunostaining laryngeal cases and all the oral squamous cell carcinoma cases were negative No significant relationship in immunoexpression of he above markers between the tow groups.
Conclusions The results of this study proved that the biological behavior namely the PCNA ,VIMENTIN and BCL-2 activities was comparable between SCC of the oral cavity and larynx with a spectrum of clinical behavior, due to the differences in location.
Keywords: squamous cell carcinoma of the oral cavity and larynx, PCNA, BCL-2, VIMENTIN.
INTRODUCTION
|
Squamous cell carcinoma of the head and neck is the sixth most common human malignancy, although it only accounts for 2%of the cancer in Westran population .
The incidance of head and neck cancer in particular tumors of the oral cavity and larynx, are increasing in developed countries, with the increase of risk being seen in young people (1).
The incidence of oral cancer is variable from region to region and the highest rates are seen in India, SriLanka, Hong Kong and Taiwan (2)
Carcinogenesis is multistep process at both phenotypic and genetic levels, resulting from multiple mutations. Non lethal genetic damage lies at the heart of carcinogenesis, this genetic damage can be defined in 4 classes:
1 Damage in normal regulatory genes-growth-promoting proto oncogen
2. Damage in gene regulates programmed cell death (apoptosis)
3. Damage in genes involved in DNA repair mechanisim
4. Damage in growth –inhibitory tumour suppressor genes. (3)
|
The first step of cancer invasion is to break down the collagen component of the basement membrane (mainly collagen IV)by brotiolytic enzymes and then degrade the intermediate protein filament of the connective tissues.Vimentin is the main intermediate fillament in the C.T(4). Although most intermediate filament are stable structures in fibroblast cells, Vimentin exists as dynamic structure serves as a biochemical carrier for low density lipoprotein(LDL) during cholesrol estrification and maintaining the flexibility of the cells(5,6)
Tissue growth depends on both the rate of cell proliferation and cell death. The increased ability of cells to proliferate is one
of the main features of malignancy. In many tumors cell kinetics has been demonstrated to correlate with malignant behavior, they are of importance in planning certain type of therapy. PCNA,a cofactor of DNA polymerase δ is generally detected in cell nucleus between G1 and M phases of cell cycle mainly in the S phase .It is a useful immunohistochemical marker of cell proliferation because its expression and distribution correlate with cellular proliferation rate and DNA synthesis .Expression of PCNA has been investigated in many cancers including oral cancer (7,8)
Recently ,basic cancer research has produced remarkable advances in our understanding of cancer biology and cancer genetics.among the most important of these advances is the reliazation that apoptosis and the gene that control it have profound effect on the malignant phenotype and it is now well documented that most cytotoxic anticancer agents induce apoptosis ,raising the intriguing possibility that defect in apoptotic programs contribute to treatment failure (9)
Bcl-2(B-cell lymphoma 2) is the founding member of the bcl-2 family of apoptosis regulates proteins encoded by the bcl-2 gene.Bcl-2derived its name from the B-cell lymphoma 2 (10, 11)
MATERIALS AND METHODS
Fifteen formalin fixed paraffin embedded tissue blocks of Oral squamous cell carinoma, and another fifteen of Laryngeal squamous cell carcinoma were retrospectively collected from laboratories’ archives and included in the study. Diagnostic confirmation was performed through examination of hematoxylin and eosin (H&E) sections. Five micrometer thick sections were cut and mounted on positively charged slides and stained immunohistochemically with monoclonal antibodies to PCNA to assess the proliferative capacity, BCL-2 to assess the apoptotic potential and Vimentin to assess the invasion. Comparisons regarding the aforementioned markers’ expressions were carried out between the two sites involved in the study.
Assessment of immunohistochemical results of PCNA
PCNA expression was evaluated semi-quantitatively. It was obtained by counting the number of positive nuclear staining, regardless to the intensity, in 1000 tumor cells from five different randomly selected representative fields in each sample using 40X objective. Immunoreactivity was classified as: (-) negative <5%, (+) low 6-25%, (++) moderate 26-50% and (+++) high 51-100% .
Assessment of immunohistochemical results of BCL-2
Only the number of cells showing cytoplasmic expression of bcl-2 was quantified by counting at least 1000 cells in five representative fields at 40X objective in each case, The extent of immunoreactivity was graded 1+ (+) if less than 25% of tumor cells were positive, 2+ (++) if 25 to 50% of cells were positive, and 3+ (+++) if more than 50% of cells were positive (12)
Assessmentof immunohistochemical results of VIMENTIN
Each histological section was examined at 40 to identify areas of maximum tumor staining. At X400, 200 cells were analyzed (in the areas of maximum tumor staining), and the percentage of positive cells was recorded. This procedure was repeated, and the average of the two percentages was recorded. These averaged values were originally stratified into four scoring groups:(a) no immune positive cells identified; (b) >10% positive tumor cells; (c) 10–50% positive tumor cells; and (d) >50%positive tumor cells.(13)
RESULTS
The age range of the patients with squamous cell carcinoma of the oral cavity was between 40 and 86 years with a mean of (62.13±12.39). For squamous cell carcinoma of the larynx, the age ranged between 32 and 66 years with a mean of (54.73±8.14). No significant statistical difference in the age distribution between the two groups was found (p=0. 0.063). The male/female ratio for oral squamous cell carcinoma was 10/5 (2:1), and it was 8/7 (1.4:1) for Laryngeal squamous cell carcinoma. No statistically significant difference was found regarding gender distribution between the groups.(table1) Regarding the locations, the majority of the cases of Oral squamous cell carcinoma were located on the buccal mucosa 7 cases (46.6%), followed by 4 (26.6%) on the maxillary bone; The other 4 sites were distributed between alveolar ridge and the tongue. Whereas Laryngeal squamous cell carcinoma cases were distributed among glottic (10 cases) 66.7%, supraglottic(4 cases) 26.7% and subglottic(1 case) 6.7%.
Histological grading was recognized for each case of oral and laryngeal squamous cell carcinoma. Two thirds of the oral cases (11 of 15) were well differentiated, another four were moderate and poorly differentiated squamous cell carcinoma. While 8 of the fifteen cases were moderately diffrentiated, and the remaining six were well with one case of poorly differentiated SCC. Regarding histological grading there was no statistically significant difference between the two groups (Oral and Laryngeal squamous cell carcinoma.)(Table 2)
PCNA immunoreactivity was recognized in 14 of the fifteen oral cases whereas in laryngeal, 12 cases were positive for PCNA and the other three were negative (fig 1, 2).No statistically significant difference in the PCNA immunoexpression between oral and laryngeal squamous cell carcinoma was found.
Collectively, 9 of the 30 cases (30%) were positive for vimentin antibody with different score values, There was no statistically significant difference in the vimentin immunoexpression between oral and laryngeal squamous cell carcinoma(fig 3,4).
Bcl-2 was expressed in one case only from fifteen immunostaining laryngeal cases(fig 5, 6) and all the oral squamous cell carcinoma cases were negative.
DISCUSSION
Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers. Although potentially curable by local radiotherapy and surgical resection, the overall 5 –years survival rate is only 50%, largely because of the propensity of some HNSCC tumors to disseminate via the lymphatic (14)
Therefore, a factor that consistently identifies patients at risk recurrent disease would help to improve disease free by allowing physician to select high–risk patients for more aggressive treatment. In addition, identifying a biologic marker of aggressiveness would help to provide new avenues for rational drug disintegrated specific molecular defect (15)
This study attempted to investigate a possible correlation between the biological behavior of oral and laryngeal SCC, in relation to proliferation, apoptosis and invasion and their histological appearance. .
PCNA immunohistochemical expression
The current result showed positive PCNA nuclear staining in 14 out of 15(93.3%) of oral SCC cases and 12 out of 15(80%) of laryngeal SCC cases, which reflect the high proliferative activity of canceroustissue.The increased PCNA expression in malignant tissue is thought to occur as a repair response, PCNA was found to play a role in DNA damage repair by combining with hMsH3(the sub unite of LMuts alpha and LMuts beta that act as cofactors in DNA mismatch repair system . Since malignant tissue is characterized by high frequencies of DNA mismatch, breakage and mutations, thus, leading to increased proliferative rate reflected by PCNA over expression (16).
Assessment of the Vimentin expression
Vimentin, a mesenchymal cell marker, associates with components of the cytoskeleton and membrane adhesions. Studies of human epithelial carcinomas have shown that vimentin expression can be correlated with tumour invasion and a poor prognosis. (17,18)
The epithelial to mesenchymal transition theory is a potentialmechanism to explain the dissemination and metastasis of carcinoma and may explain the aberrant expression of vimentin in epithelialtumors(19). To disseminate and metastasize, cohesive epithelialcells have to lose their stable, polarized, non migratory propertiesand transdifferentiate into migratory cells acquiring mesenchymalcharacteristics (20). Elevated andaberrant expression of vimentin have been found to correlate well with these fetures.
In the current study vimentin expression was 33.3% and 23% from 15 cases of LSCC and 15 OSCC respectively; This may correlate with a better prognosis than tumors with high vimentin expression.
Assessment of BCL-2 expression
By means of immunohistochemistry we estimated the level of expression of bcl-2 proteins in a series of the 30 formalin fixed, paraffin-embedded samples of oral and laryngeal squamous cell carcinoma and the results was 1(6%) case in laryngeal and none of the oral cases was positive ,while other studies found, none of the cases were positive in SCC of the skin; 26.2% from149 LSCC, 17%from 90 OSCC and 25%from 154 LSCC(21,22,23,24)respectively. The discrepancies might be attributed to numbers of reasone one of them is small sample size, the other one is lost of bcl-2 from the basal layer that may be result from Transcriptional suppression of BCL-2 which may also result from modulation of the negative response element located at the 5′ untranslated region (25).
BCL-2 is known to have antiproliferative effects, by delaying progression to S phase from quiescence (26). In addition, the antiproliferative effect of BCL-2 has been shown to inhibit tumour progression in animal tumours.(27,28) Therefore, loss of the suppressive effects of BCL-2 may be advantageous for potentially malignant and malignant oral keratinocytes. A suppressive effect of BCL-2 on proliferation is consistent with the study of (29) who reported increased proliferative activity (as assessed by Ki-67 labelling) in basal cells of OSCC, which had lost BCL-2. Therefore, loss of BCL-2 in oral keratinocytes may be involved in dysplastic and malignant progression of oral epithelium by making oral keratinocytes more responsive to mitotic stimuli.
In conclusion, no significant relations were found among the immunohistochemical findings obtained by PCNA, BCL-2and VIMENTIN considering the proliferation, apoptosis and invasion potential when correlated with the clinical finding and the histological grading systems obtained by the traditional H&E staining in both tumor sites.
REFERENCES
- Nanci A.Ten Cat s Oral Histology Development,Structureand function.2008;7th edition:54-79.
- Ghoshal S,Mallick I, Panada N,Sharma,S.Carcinoma of the buccal mucosa,analysis of clinical presentation out come and prognostic factor.Oral incology 2006;42:533-539.
- Kumar V, Abbas AK, Fausto N.,Mitchell RN. Robbins Basic Pathology.8th ed. Saunders, 2007.
- Leader M,Collins M,Petal J and Henry K.Vimentin :an evaluation of its role as atumormarker.Histopathology.1987;11(1):63-72.
- Sarria AJ,Panini SR, and Evans RMA functional role of vimentin intermediate filament in the metabolism of lipoprotein derived cholesterol in human SW-13 cells. J Bio Chem 1992; 267(27):19455-63.
- Chiang CP,Lang Mj, Liu BY, Wang JT, Leu JS, Hahn LJ. Expression of proliferating cell nuclear antigen (PCNA) in oral sub mucous fibrosis oral epithelial hyperkeratosis and oral epithelial dysplasia in Taiwan. Oral Oncology 2000; 63:353-359.
- Lavezzi AM, Milei J,Grana DR, Flenda F, Basellini A, Matturri L.Expression pf c-fos, p53 and PCNA in the unstable atherosclerotic carotid plaque.International Journal of Cardiology 2003;92:59-63.
- Low SW and Lin AW. Apoptosis in cancer carcinogensis 2003;21:458-495.
- Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. “Cloning of the chromosome breakpoint of neoplastic B cells with the t (14; 18) chromosome translocation”. Science 1984; 226 (4678): 1097–9.
- Cleary ML, Smith SD, Sklar J. “Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation”. Cell,October 1986;47 (1): 19–28.
- Patricia A, Dawn A, James R, Elisabeth A, and Mary J C. Association between Keratin and Vimentin Expression, Malignant Phenotype, and Survival in Postmenopausal Breast Cancer Patients. Clinical Cancer Research 1999; 5: 2698–2703.
- Deniz K, Yuce I, Cagli S, Guney E. Expression of PCNA and bcl-2 in basaloid squamous cell carcinoma of the larynx, a controlled study. Clinical report 2005; 17: 920.
- Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17:548–558.
- Manda M, Myers N,Lippman SM. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 2008; 112:2088–2100.
- Giils C, Thompson EW. The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J1996; 2: 83-96.
- Kokkinos MI, Wafai R, Wong MK.Vimentin and epithelial-mesenchymal transition in human breast cancer—observations in vitro and in vivo. Cells Tissues Organs 2007; 185: 191-203.
- Lauwer GY, Scott GV, Karpeh MS.Immunohistochemical evaluation of BCL-2 protein expression in castric adenocarcinoma. Cancer 1995; 75:2209-13.
- Pruniri G, Pignataro L, Carboni N.Clinical relevance of p53 and bcl-2 protein over-expression laryngeal squamous cell carcinoma.Int. J. Cancer (Pred. Oncol.) 1998; 79: 263–268.
- Lomozio E, Mignogna MD, Grassi R,Ferarri F.Expression of bcl-2 in oral squamous cell carcinoma:an immunohistochemical study of 90 cases with clinicopathological correlations.J Bio Chem 2003;10(2):285-91.
- Sulkowska M, Famulsk W, Sulkowski S. ReszecCorrelation between Bcl-2 Protein Expression and SomeClinicopathological Features of Oral Squamous Cell CarcPol J Pathol 2003; 1:49-52.
- Miyashita T, Harigai M, Hanada M.Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54:3131–5.
- Korne I, WeberNordt R, Pfaff P.Analysis of a regulatory element in the 5′-untranslated region of the bcl-2 gene. FEBS Lett 1997; 406:31–2.
- Huang DC, Reilly LA, Strasser A.The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16:4628–38.
- Murphy KL, Kittrell FS, Gay JP.Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene 1999; 18:6597–604.
- Furth PA, Bar-Peled U, Li M. Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model. Oncogene 1999; 18:6589–96.
- Loro LL, Johannessen AC, Vintermyr OK. Decreased expression of bcl-2 in moderate and severe oral epithelial dysplasias. Oral Oncol2002; 38:691–8.
13. Wolf G, Lippman SM, and Laramore G.”Head and Neck Cancer”In Holland JF, Frei E, Bast RC Jr et al, (eds). Cancer Medicin 3rd 1993; .1211-1278.
14. Smith BD, Smith GL, Carter D, Sasaki CT. Prognostic significant of vascular endothelial growth factor protein level in oral and oropharyngeal squamouscell carcinoma. J Clin Oncol 2000; 18(10): 2046-2052.
15. Kimos MC, Wang S,Borkowski A, Yang GY,Yang CS, Perry K,Olaru A, Deacu E, Sterian A, Cottrell J,Papadimitriou J,Sisodia L, Selaru FM,Mori Y,Xu Y,Yin J, Abraham JM, Meltzer SJ. Esophagin and proliferating cell nuclear antigen (PCNA) are biomarkers of human esophageal neoplastic progression. Int J Cancer. 2004; 111(3):415-7.
Fig(1)Photomicrography showing
Well differentiated SCC of the oral cavity with positive PCNA immunostaining of the malignant nuclei (X40)
Fig(2)Photomicrography showing
Well differentiated SCC of the larynx with positive PCNA immunostaining of the malignant nuclei (X40)
Fig(3)Photomicrography showing
Moderately differentiated SCC of the oral cavity with positive Vimentin immunostaining of the malignant cytoplasm(X40)
Fig(4)Photomicrography showing
Moderately differentiated SCC of the larynx with positive Vimentin immunostaining of the malignant cytoplasm (X40)
Fig(5)Photomicrography showing
Moderately differentiated SCC of the larynx with positive BCL-2 immunostaining of the malignant cytoplasm (X10)
Fig(6)Photomicrography showing
SCC of Oral cavity with 87positive BCL-2 immunostaining of the lymphoid tissue (internal control)(X40)
|
WELL |
MODERATE |
POOR |
ORAL |
11 73.3% |
2 13.3% |
2 13.3% |
LARYNGEAL |
6 40% |
8 53.3% |
1 6.7% |
Pearson’s Chi-square |
0.135NS |
||
Total |
17 .56.5% |
10 33.3% |
3 10% |
Fig (7) Photomicrography showing
SCC of the larynx with positive BCL-2 immunostaining of the lymphoid tissue (internal control) (X40)
Table(1)Case distribution according to age and sex
Tumors |
Sex |
Age |
||
Male |
Female |
Range |
Mean±SD |
|
Oral |
N=10 66.7% |
N=5 33.3% |
40-86 |
62.1333±12.39163 |
Laryngeal |
N=8 53.3% |
N=7 46..7% |
32-66 |
54.733±8.13692 |
Tests |
Pearson Chi square test= 0.456 ** |
T test= 0.063** |
||
Total |
N=18 60% |
N=12 40% |
32-86 |
40.562±13.649 |
Table(2) Case distribution according to histological grading
NSNon-significant difference (p> 0.05)